Cannabis & Wellness

A deadly, vaccine-less Ebola strain is spreading in Central Africa. As governments scramble, the CDC Foundation deploys its most potent weapon: agile funding.

As Capricor presents its late-stage DMD drug and novel exosome platform, can it convince investors it has the key to both patient impact and market success?

An aging world and failing antibiotics are driving a surge in pneumonia. Now, a new generation of therapies is being built to fight back. Here's how.

As GLP-1 drugs dominate, a UK biotech reveals a new drug that targets mitochondria, promising superior fat loss while preserving precious muscle mass.

With expanded coverage for 52 million Americans, Tonix Pharmaceuticals' TONMYA® is not just a drug launch; it's a market disruption for chronic pain.

A CPG veteran launches Lioness, a functional gummy snack for women. Can timed ingredients and a massive retail launch redefine the wellness market?

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Wilson Elser’s 2026 Chambers rankings reveal more than legal wins; they map a strategy of mastering niche markets from cannabis law to NTSB disasters.

VFF's balance sheet didn't need the cash, so why take it? A deep dive into a strategic capital raise that's less about liquidity and more about legitimacy.

A family-owned hemp company's recent award from Beer Connoisseur is no fluke. It’s a key signal of the booming, multi-billion-dollar THC beverage market.

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

The men's supplement industry is shifting from pure performance to holistic vitality. A new launch reveals the economic and scientific forces driving this change.

A Maine edibles brand is launching nationwide, but the real story is its strategic navigation of legal gray areas and its debut at the Food & Wine Classic.

Swiss brand NIANCE is moving beyond creams to build a global ecosystem of longevity clinics. It's a high-stakes bet on science in a trillion-dollar market.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.